• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

PharmAust share price rises on promising trial outcome (ASX:PAA)

Like 0

By Ryan Clarkson-Ledward, Tuesday, 12 May 2020

Today, PharmAust Ltd [ASX:PAA] is the latest in a long list to add to the field of cancer treatment. Delivering a trial outcome that has helped lift the PAA share price as well hopes for a bigger breakthrough to come...

When it comes to tackling cancer, many biotech’s have tried and failed.

It’s been the ruin of many companies, both public and private, over many years. But that doesn’t stop more from trying each and every year.

Which is fantastic, because every now and then we at least make progress.

Today, PharmAust Ltd [ASX:PAA] is the latest in a long list to add to the field. Delivering a trial outcome that has helped lift the PAA share price as well hopes for a bigger breakthrough to come.

At the very least, it is bound to help man’s best friend…

Cancer-free canines

PharmAust is currently in midst of testing its Monepantel tablets. A drug that they believe could offer a solution for managing cancer.

However, this trial doesn’t involve human patients. Instead, the drug is being tested in dogs first.

PharmAust already has plans to run human trials as well, it’s just not locked in just yet. But the good news is the canine trial has shown some promising results.

Today the company showed off its latest findings. In particular, the better response in this ‘pill’ trial compared to their last ‘liquid’ one. And to the surprise of PharmAust, one dog even saw strong signs of recovery:

‘Having the monepantel tablets achieve a 60% reduction in tumour burden in one dog, with one lymph node returning to normal, is a terrific and unexpected outcome.’

It may just be the trigger that gives this biotech the push it needs. Because despite the success of the trial, it was very narrow.

With only seven dogs included in the study, one of which failed to meet necessary protocol, what PharmAust really needs is more data. The kind of data that will only come from a Phase III trial.

So, once this current (Phase II) trial is finalised, that should be a very real possibility.

The next step

Naturally getting the monepantel treatment to a Phase III trial will be huge. Not only for use in canines, but also potentially to speed up human trials.

Obviously they can’t afford to rush the trials themselves, but positive data could help prioritise testing of the drugs in people. Whether the results will be as promising is the ultimate question.

Still, for this tiny biotech stock any win counts. And for shareholders it’s the kind of breakthrough that will put a smile on their face.

It’s yet another reminder of the explosivity of the biotech sector. A field that is filled with stocks that can make astonishing overnight gains. All it takes is one amazing trial result or discovery.

However, they can crash just as hard and fast as well…

That’s why investing in these speculative companies certainly isn’t for everyone. There is the potential for a lot of reward, but also a lot of risk. Which is why you need to stay informed.

Here at Money Morning, that’s what were all about. Bringing readers unique insights from across the market to help them make more informed investing decisions. If that sounds like something you’re interested in, then click here to learn more.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

Advertisement:

Will this no-name stock rule the ‘Aussie Mining Boom 2025’?

It’s showing all the traits, ambition and foresight that Andrew Forrest’s Fortescue Metals had in the early 2000s.

Market cap just $270 million.

And a gameplan that’s addressing many of the same challenges Fortescue Metals Group faced in the 2000s.

This very small company is about to unlock a very big deposit.

The largest of its kind IN THE WORLD.

Its potential has arrived from nowhere, busting into ‘Tier 1’ status and attracting mining behemoths…including Rio Tinto.

This has all the makings of a classic rags to riches story. Click here for the full take.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI’s Prisoner Dilemma
    By Charlie Ormond

    Today, it’s optional Orb scans for crypto rewards. Tomorrow, could it be mandatory scans for jobs, benefits, or even voting?

  • Rate Cut Boom Unleashed
    By Murray Dawes

    US stocks continue to fly as we approach the Feds interest rate decision next week. A mortgage refinancing boom is about to begin so investors need to position themselves. Aussie stocks have been struggling and Murray shows you what needs to happen to spark the buying again. Murray and Callum also point out three cryptocurrencies that are ripe for a run.

  • America on a War Footing – The Copper Strategy Part II
    By James Cooper

    As far as the world’s two largest superpowers are concerned, Africa’s mineral wealth remains up for grabs. Read on to find out why Africa’s minerals could be a geopolitical flashpoint in future.

Primary Sidebar

Latest Articles

  • OpenAI’s Prisoner Dilemma
  • Rate Cut Boom Unleashed
  • America on a War Footing – The Copper Strategy Part II
  • Goodbye from Callum, and good luck!
  • Who is the most important?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988